

QUARTERLY MONITORING REPORT
FLORIDA FAMILY PLANNING SECTION 1115 DEMONSTRATION

State: Florida

Demonstration Reporting Period: January 1, 2025 – March 31, 2025

Demonstration Year: 27

Approved start and end date of the Demonstration: March 8, 2019 – April 30, 2025

A. Executive Summary


1. The Family Planning Waiver (FPW) provides family planning services to women ages 14 through 55 years with family income at or below 191 percent of the Federal Poverty Level (FPL) who have lost or are losing Florida Medicaid eligibility and are not otherwise eligible for the Children’s Health Insurance Program (CHIP) or enrolled in health insurance coverage that provides family planning services. Eligibility is limited to a period of up to 24 months following the loss of Medicaid coverage, as authorized in section 409.904(5), Florida Statutes, to provide transitional coverage for those losing Medicaid eligibility.

The State is required to submit a quarterly report summarizing the events that occurred during the quarter or are anticipated to occur in the near future that affect healthcare delivery. This report is the third quarter report for demonstration year (DY) 27 covering the period of January 1, 2025, through March 31, 2025.

Beginning in DY 22 and continuing through DY 25, Florida and the nation were affected by the COVID-19 public health emergency (PHE) which impacted enrollment.

2. Program Updates

- a. Current Trends and Significant Program Activity
 - i. There was a slight decrease in FPW enrollment from the second quarter of DY 27 (321,569) to the third quarter of DY 27 (321,029). Additionally, enrollment increased by 12,472 enrollees from Quarter 3 of DY 26 (308,557) to Quarter 3 of DY27 (321,029).
 - ii. Participation within the waiver remained the same in Quarter 3 of DY 27 (4%) as compared to Quarter 3 of DY 26 (4%).
 - iii. Enrollment and participation numbers for the past five years for the period of January – March are presented in the chart below.



3. Policy Issues and Challenges

As part of the eligibility transition, Participation Monitoring and Program Outreach and Education for the FPW has recently transitioned from the Florida Department of Health (DOH) to the Florida Department of Children and Families (DCF). Quarterly data is not available to the Agency for Health Care Administration (Agency) at this time. The Agency is working with DCF to be able to report data in future reports.

The Agency has not considered any new policies related to legislative/budget activity or amendments to the currently approved demonstration.

B. Participation Monitoring

To promote the Family Planning Waiver, DOH and the county health departments use a variety of strategies, including working with community partners, posting flyers and other promotional materials throughout the county health departments, hosting and/or participating in community outreach events, and proactively contacting individuals who may be eligible.

C. Utilization Monitoring

The state will summarize utilization through a review of claims/encounter data for the demonstration population in the subsequent tables. This includes the following:

Table 1. Utilization Monitoring Measures

Topic	Measure [reported for each month included in the report]
Utilization Monitoring	Unduplicated Number of Enrollees by Quarter
	Unduplicated Number of Beneficiaries with any Claim by Quarter (by key demographic characteristics such as age, gender, and income level)
	Utilization by Primary Method and Age Group
	Total number of beneficiaries tested for any sexually transmitted disease
	Total number of female beneficiaries who obtained a cervical cancer screening
	Total number of female beneficiaries who received a clinical breast exam

Tables 1 through 8 were developed by the Centers for Medicare and Medicaid Services (CMS) to specify the utilization data for the state to report for the demonstration population by quarter or by year. This quarterly report template is included in the CMS issued Standards, Terms, and Conditions authorizing this waiver.

Table 2: Unduplicated Number of Enrollees by Quarter

	Number of Female Enrollees by Quarter				
	14 years old and under	15-20 years old	21-44 years old	45 years old and older	Total Unduplicated Female Enrollment*
Quarter 1	2,042	44,901	240,132	42,754	329,829
Quarter 2	1,857	41,342	235,573	42,797	321,569
Quarter 3	1,750	39,465	236,378	43,436	321,029
Quarter 4					

*Total column is calculated by summing columns 2-5.

Table 3: Unduplicated Number of Beneficiaries with any Claim by Age Group per Quarter in the Demonstration Year (to date)

	Number of Females Who Utilize Services by Age and Quarter					
	14 years old and under	15-20 years old	21-44 years old	45 years old and older	Total Female Users *	Percentage of Total Unduplicated Female Enrollment
Quarter 1	4	851	5,008	341	6,204	2%
Quarter 2	9	1,490	9,614	685	11,798	3%
Quarter 3	12	2,055	13,926	1,027	17,020	4%
Quarter 4						

*Total column is calculated by summing columns 2-5.

Table 4: Contraception Utilization by Age Group per Demonstration Year (to date)**

Effectiveness	Users of Contraceptives					
		14 years old and under	15 – 20 years old	21 – 44 years old	45 years old and older	Total
Most and Moderately Effective*	Numerator	8	924	4,098	160	5,190
	Denominator	12	2,055	13,926	1,027	17,020
Long-acting reversible contraceptive (LARC)*	Numerator	1	129	716	13	859
	Denominator	12	2,055	13,926	1,027	17,020
Total	Numerator	9	1,053	4,814	173	6,049
	Denominator	12	2,055	13,926	1,027	17,020

*This measure is calculated as per the Medicaid and CHIP Child and Adult Core Set measure for contraceptive care for all women.

**Guidance for Reporting on pages 42–44 of the Core Set of Health Care Quality Measures for Adults Enrolled in Medicaid 2019 Technical Specifications and Resource Manual was used to calculate the measures for Table 4.

Table 5: Number of Beneficiaries Tested for any STD by Demonstration Year

Test	Total Tests	
	Number	Percent of Total Enrolled Females
Unduplicated number of beneficiaries who obtained an STD test*	4,489	1.038%

*Used procedure codes: '86592', '86593', '86689', '86694', '86695', '86696', '86701', '86702', '86703', '86706', '86707', '86762', '86803', '87070', '87075', '87081', '87086', '87088', '87110', '87164', '87205', '87206', '87210', '87252', '87270', '87273', '87274', '87340', '87341', '87350', '87390', '87480', '87481', '87490', '87491', '87510', '87511', '87516', '87520', '87521', '87522', '87528', '87529', '87530', '87534', '87535', '87590', '87591', '87592', '87623', '87624', '87660', '87661', '87810', '87850'

Table 6: Total Number of Female Beneficiaries who obtained a Cervical Cancer Screening

Screening Activity	Number	Percent of Total Enrolled Females
Unduplicated number of female beneficiaries who obtained a cervical cancer screening*	2,839	0.656%

*Used procedure codes: '88141', '88142', '88143', '88150', '88152', '88153', '88155', '88164', '88165', '88166', '88167', '88174', '88175.'

Table 7: Breast Cancer Screening

Screening Activity	Number	Percent of Total Enrolled Females
Unduplicated number of female beneficiaries who received a Breast Cancer Screening*	0	N/A

*Breast cancer screenings are done as part of a routine physical (evaluation and management), and as such are not able to be identified in this format.

Table 8: Post-Partum Contraceptive Care*

Screening Activity	Number	Percent of Total Enrolled Females
Among female beneficiaries between the ages of 15 to 20 who had a live birth, the percentage that was provided within 3 and 60 days of delivery, a most effective or moderately effective method of contraception:	0	0%
Among female beneficiaries between the ages of 15 to 20 who had a live birth, the percentage that was provided within 3 and 60 days of delivery, a long-acting reversible method of contraception (LARC).	0	0%
Among female beneficiaries between the ages of 21 to 44 who had a live birth, the percentage that was provided within 3 and 60 days of delivery, a most effective or moderately effective method of contraception:	0	0%
Among female beneficiaries between the ages of 21 to 44 who had a live birth, the percentage that was provided within 3 and 60 days of delivery, a long-acting reversible method of contraception (LARC).	0	0%

*Florida does not enroll individuals within 3 and 60 days of delivery into the Family Planning Waiver. These individuals still have access to full State Plan Medicaid coverage through 12 months postpartum.

D. Program Outreach and Education

1. In order to promote the Family Planning Waiver, DOH and the county health departments use a variety of strategies, including working with community partners, posting flyers and other promotional materials throughout the county health departments, hosting and/or participating in community outreach events, and proactively contacting individuals who may be eligible.

2. The DOH operates a toll-free hotline, the Florida Family Health Line. The goal of the hotline is to improve the health status of Florida's pregnant women and their children by providing callers with information on helpful community resources and answering basic questions about pregnancy, breastfeeding, childbirth education and other pregnancy-related concerns. The hotline provides callers with information about the FPW.

E. Program Integrity

DCF conducts eligibility determinations for the FPW. DCF evaluates women aged 14 to 55 who have lost or are at risk of losing their Medicaid eligibility. These individuals are assessed for potential coverage under the FPW Medicaid coverage group. To qualify, a woman must meet specific Medicaid technical eligibility requirements, including residency, citizenship, and possession of a Social Security Number (SSN).

The Agency contracts with Florida State University (FSU) to provide an independent evaluation of the FPW program. During the 3rd quarter, FSU received and validated the Medicaid data needed for the DY26 (SFY23/24) Evaluation Report. FSU constructed quantitative and qualitative surveys that were administered during the 3rd quarter. The surveys will be used to answer RQs 6, 9, and 10 as outlined on the CMS approved evaluation design. Additionally, FSU submitted the FPW DY26 (SFY2023-2024) Interim Evaluation Report to the Agency on April 7, 2025, which addresses research questions 1, 6, 7, 8, 9 and 10 as outlined in the CMS approved evaluation design.

F. Grievances and Appeals

There were no grievances/appeals filed during Quarter 3 and subsequently no fair hearings.